Cargando…
Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia
Despite progress in both primary and secondary prevention, cardiovascular diseases (CVD) are still the largest group of ailments contributing to morbidity and mortality worldwide. Atherosclerotic changes, the primary pathological substrate for CVD, are closely related to hypercholesterolemia. Theref...
Autores principales: | Toth, Stefan, Pella, Dominik, Fedacko, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394273/ https://www.ncbi.nlm.nih.gov/pubmed/32737796 http://dx.doi.org/10.1007/s40119-020-00191-6 |
Ejemplares similares
-
Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels
por: Rehberger Likozar, Andreja, et al.
Publicado: (2022) -
Analysis of Risk Factors in Patients with Subclinical Atherosclerosis and Increased Cardiovascular Risk Using Factor Analysis
por: Pella, Zuzana, et al.
Publicado: (2021) -
Coenzyme Q10 Modulates Remodeling Possibly by Decreasing Angiotensin-Converting Enzyme in Patients with Acute Coronary Syndrome
por: Singh, Ram B., et al.
Publicado: (2018) -
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients
por: Tóth, Štefan, et al.
Publicado: (2017) -
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)